Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Incyte (INCY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.
Best Growth Stocks to Buy for February 3rd
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022
5 Corporate Bigwigs to Buy Ahead of Earnings Next Week
by Nalak Das
Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.
Zacks.com featured highlights include: Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc
by Zacks Equity Research
Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.
5 Cheap Dividend Growth Stocks to Bet Amid Volatility
by Sweta Killa
Pfizer (PFE), Kroger (KR), Archer-Daniels (ADM), HP Inc. (HPQ) and Jones Lang (JLL) seems compelling cheap picks amid volatility.
Best Growth Stocks to Buy for February 2nd
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 2, 2022
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $53.07, marking a +0.72% move from the previous day.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.
Best Growth Stocks to Buy for February 1st
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 1, 2022
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer
by Zacks Equity Research
The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
by Zacks Equity Research
While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.
Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Best Growth Stocks to Buy for January 31st
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022